In this thesis, I develop a history of thyroid hormone treatment (THT) that centers on the bodies of animals and women between 1890 and 1970. This history contextualizes the current debate between two forms of THT, desiccated and synthetic. Drawing on the discourses present in biomedical journals, I trace how medical practitioners used the animals and women to demonstrate and make sense of THT's effectiveness over time. As such, I study what Catherine Waldby terms the "biomedical imaginary" or the speculative fabric of scientific thought, to demonstrate how an "ordinary" medical technology crosses and reinforces the conceptions of gender and animality. THT emerged in the 1890s as an organotherapy, or a medicine made from animal organs. Like other organotherapies, general physicians used THT for a wide variety of ailments that had not been scientifically proven through the practices of vivisection or animal experimentation. From its emergence, THT served as a site of tension between scientific researchers and general practitioners. This tension only increased when a synthetic form of THT was invented in the 1920s, when scientific researchers embraced synthetic THT and general practitioners continued using desiccated THT. At the center of the controversy were the productive and subversive relationships of animals and women to biomedical meaning-making. Over the twentieth century, methods of defining THT's effectiveness and purity were defined in opposition to these bodies. These chemical measures combined the specialist and physician's measurement of THT's clinical effectiveness, which led to a preference for synthetic THT. / Master of Science

Hyperthyroidism is the most common feline endocrinopathy. 131I is the treatment of choice, and over 50,000 cats have been treated using an empirical fixed dose. Better treatment responses could be achieved by tailoring the dose based on the severity of disease. Scintigraphy is the best method to quantify the severity of the disease. Previously established scintigraphic quantitative methods, thyroid to salivary ratio (T:S ratio) and % dose uptake, are the most widely recognized measurements. Recently, the thyroid to background ratio (T:B ratio) has been proposed as an alternate method to assess function and predict 131I treatment response. The purpose of this study was to determine the best location of a background ROI, which should be reflective of blood pool activity. We also hypothesized that the T:B ratio using the determined background ROI would provide improved correlation to T4 when compared to T:S ratio and % dose uptake in hyperthyroid cats. Fifty-six hyperthyroid cats were enrolled. T4 was used as the standard measure of thyroid function and was obtained prior to thyroid scintigraphy and 131I therapy. Blood samples were collected at the time of scintigraphy and radioactivity within the sample was measured. The plasma radioactivity was compared to the background ROI count densities in 8 anatomic regions using linear regression analysis for 55 cats. One cat was excluded from the study because of an injection error during scintigraphy. T:B and T:S ratios, and % dose uptake on scintigraphy were then compared to serum T4 by linear regression analysis for 39 cats. Sixteen cats were excluded because of recent methimazole or Y/D diet use, or incomplete data. The heart ROI correlated best to plasma pertechnetate activity (r = 0.70). % dose uptake correlated best to serum T4 (r = 0.74), followed by T:S ratio (r = 0.66), followed by the T:B ratio using the heart ROI (r = 0.59). Placing an ROI over the heart is the best method of quantifying plasma radioactivity. T:B ratio using the heart ROI as the background is a good predictor T4 but percent dose uptake and T:S ratio proved to be better predictors of T4 than any of the T:B ratios. Therefore, our hypothesis was not supported. The T:B ratio may not provide the best scintigraphic measurement of thyroid function. Hence it is unlikely to accurately predict treatment response to 131I therapy. / Master of Science

The effect of thyroid hormones on nuclear RNA synthesis was studied in vitro. Results indicated that thyroid hormones added to cell-free rat liver homogenates, in the presence of IMP as a precursor of purine nucleotides and necessary substrates, stimulated orotic acid-6-¹⁴C incorporation into nuclear RNA. The stimulatory effect was observed with 10⁻⁹ M triiodo-L-thyronine (L-T₃ )and with 10⁻⁵ M thyroxine. Thyroid hormones had no effect on the incorporation of UTP-³H into nuclear RNA which is evidence that the primary site of action of the hormones is in the cytoplasm, i.e., the conversion of IMP to AMP and to GMP. The net effect is to maintain a high adenine nucleotide/guanine nucleotide ratio. The incorporation of UTP-³H into nuclear RNA was enhanced when the ATP/GTP ratio was greater than one as compared to that when the ratio was one, and it was inhibited when the ratio was less than one. The relative concentrations of the purine nucleotides had a profound effect on nuclear RNA synthesis. DNase and actinomycin D inhibited nuclear RNA synthesis induced by a high ATP/GTP ratio. Based on these results, it was proposed that thyroid hormones regulate the synthesis of AMP and GMP from IMP and maintain a high adenine nucleotide/ guanine nucleotide ratio which enhances the synthesis of a specific RNA. The significance of the maintenance of a high adenine nucleotide/guanine nucleotide ratio and the consequences of the synthesis of a specific RNA were discussed. / Master of Science

Tricyclic antidepressants have been shown to alter thyroid function in man and laboratory animals, but have not been evaluated in the dog. The effect of administration of clomipramine on canine thyroid function was studied in a prospective protocol in which 14 mature, healthy dogs were administered clomipramine (3 mg/kg PO q12h) for 112 days. Thyroid-stimulating hormone (TSH), total thyroxine (T4), total 3,5,3' triiodothyronine (T3), free thyroxine (fT4), and 3,3',5' triiodothyronine (reverse T3; rT3) concentrations were measured on selected days. Thyrotropin-releasing hormone (TRH) response tests were performed concurrently. Repeated measures analysis of variance was applied to test for effects of day of treatment; when significance (p < 0.05) was noted, it was further investigated using orthogonal polynomial trends. Significant decreases were found in serum T4 (26 ± 1.2 to 17 ± 0.5 nmol/L, p < 0.001), fT4, (29 ± 2.4 to 19 ± 1.3 pmol/L, p < 0.0002), and rT3 (1.2 ± 0.1 to 0.83 ± 0.08 nmol/L, p < 0.0001) concentrations. The effect of time on serum T3 concentration was also significant (p < 0.0001), but no consistent trend could be identified. No significant effect of time was noted in either pre- or post-TRH TSH concentrations. The results of this study indicate that significant and substantial decreases in T4 (35%), fT4 (38%), and rT3 can occur during clomipramine administration. Long-term administration of clomipramine may result in a misdiagnosis of hypothyroidism if a dog is tested while taking this medication and, since decreased serum fT4 occurs, hypothyroidism may result. / Master of Science

Das Neuroblastom ist der dritthäufigste maligne Tumor im Kindesalter und ist für 15% der Todesfälle durch Krebs bei Kindern unter 14 Jahren verantwortlich. Viele molekularbiologische Vorgänge, die zu der heterogenen Prognose der Patienten beitragen, sind noch nicht verstanden. Als Hauptrisikomerkmal stellt sich die Amplifikation und erhöhte Expression von MYCN dar. In Vorarbeiten der Arbeitsgruppe von Prof. Christiansen zeigte MYCN Einfluss auf die Genregion von Thyroid Cancer 1 (TC1), das als neuer Marker für maligne Schilddrüsenkarzinome erkannt wurde. In der vorliegenden Arbeit wurden erste Untersuchungen zur prognostischen Bedeutung von TC1 im Neuroblastom, sowie die Charakterisierung eines TC1 Überexpressionsphänotyps humaner Neuroblastomzelllinien unter Einfluss von MYCN durchgeführt. Es wurde ein Überexpressionsvektor von TC1 in die Neuroblastomzelllinie SH-EP eingebracht, welche über ein aktivierbares MYCN- Konstrukt verfügt. Dieser neue Phänotyp wurde bezüglich der Proliferation, des Zellzyklus und der Apoptose im Vergleich zu einer Kontrollzelllinie ohne Überexpression untersucht. Eine In-silico Recherche in der Versteeg Neuroblastomdatenbank ergab eine deutlich bessere Überlebenswahrscheinlichkeit für Patientin mit hoher TC1 Expression. Es konnte gezeigt werden, dass MYCN Amplifikation und Expression in einem Panel von Neuroblastom Zelllinien nicht mit der TC1 Expression korrelieren. Die spezifische Aktivierung von MYCN führte hingegen zu einer Expressionssteigerung von TC1. Weiterhin zeigte sich, dass eine TC1 Überexpression die Proliferation hemmt, indem es die MYCN induzierte G1- S- Phasen- Transition inhibiert. TC1 zeigt antiproliferative Eigenschaften im Zellkulturmodell und stellt sich als neuer prognostisch günstiger Parameter im Neuroblastom dar.

ABSTRACT Thyroid disease is one of the most common endocrine disorders in clinical practice. Critical illness is often associated with alterations in thyroid hormone functions. Thyroid dysfunction is a serious matter if managed inaccurately; it may increase morbidity and mortality. The purpose of this Doctor of Nursing Practice project is to identify the knowledge, attitudes, behaviors and practice of advanced practice nurses (acute care nurse practitioners (ACNP) and adult gerontology acute care nurse practitioners (AGACNP)) on current thyroid dysfunction management in the acute care setting. The DNP project demonstrated that most acute care nurse practitioners believe that TD screening, diagnosis and management is important in the acute care setting. The survey results also indicated that most of the AGACNP/ACNPs would initiate treatment while managing patient in an acute care setting and will likely collaborate with endocrinology for overall management or follow ups to ensure quality and comprehensive care in management of TD. Keywords: thyroid disease, thyroid dysfunction, identify, knowledge, attitudes, behaviors, acute care

Investigations have shown that the hypothalamus and pituitary respond to decreases in body temperature by stimulating thyroid release of T_3 and T_4 . This study was designed to bypass the control of the hypothalamus and pituitary gland and investigate the direct effect of temperature on the thyroid gland. Hypothermia was by an in vivo isolated perfusion of the thyroid gland. Radio-immunoassay was used to measure T_3 and T_4 concentrations. Significant increases were observed in animals perfused between 36º and 25ºc. These results indicate that the thyroid gland is directly effected by decreased temperature and that it is capable of exerting control over body temperature independent of the hypothalamus and pituitary gland. Lower perfusion temperatures produced no significant increases.

Thyroid disruptions by xenobiotics have been associated with a broad spectrum of severe adverse human health effects, such as impaired brain development and metabolic syndrome. Ingestion of indoor dust and contact with industrial chemicals are two significant human exposure routes of thyroid hormone disrupting chemicals (THDCs), raising serious concerns for human health. However, it is a laborious and costly process to identify THDCs using conventional experimental methods, due to the number of chemicals in commerce and the varieties of potential disruption mechanisms. In this thesis, we are aimed at in silico identification of novel THDCs targeting transthyretin (TTR) and thyroid hormone receptor (THR) among dust contaminants and commonly used industrial chemicals. In vitro assays were used to validate the in silico prediction results. Co-crystallization and molecular dynamics (MD) simulations were applied to reveal binding modes of THDCs at the studied biological targets and to explain their intermolecular recognition. The main findings presented in this thesis are: 1. Over 144 environmental pollutants have been confirmed as TTR-binders in vitro and these cover a wide range of environmental pollutants and show distinct chemical profiles including a large group of halogenated aromatic compounds and a second group of per- and polyfluoroalkyl substances. (Paper I) 2. In total 485 organic contaminants have been reported to be detected in household dust. The developed QSAR classification model predicted 7.6% of these dust contaminants and 53.1% of their metabolites as potential TTR-binders, which emphasizes the importance of metabolic bioactivation. After in vitro validation, four novel TTR binders with IC50 ≤ 10 µM were identified, i.e. perfluoroheptanesulfonic acid, 2,4,2',4'-tetrahydroxybenzophenone (BP2), 2,4,5-trichlorophenoxyacetic acid, and 3,5,6-trichloro-2-pyridinol. (Paper II) 3. The development of a robust structure-based virtual screening (VS) protocol resulted in the prediction of 31 dust contaminants as potential binders to THRβ1 including musk compounds, PFASs, and bisphenol A derivatives. The in vitro experiments confirmed four compounds as weak binders to THRβ1, i.e. 2,4,5-trichlorophenoxyacetic acid, bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether, 2,4,2',4'-tetrahydroxybenzophenone, and 2,4-dichlorophenoxyacetic acid. (Paper III) 4. We revealed the binding conformations of perfluorooctanesulfonic acid, perfluorooctanoic acid, and BP2 in the thyroxine binding sites (TBSs) of TTR by co-crystallizing TTR with the three compounds. A VS protocol was developed based on the TTR complex structures that predicted 192 industrial chemicals as potential binders to TTR. Seven novel TTR binders were confirmed by in vitro experiments including clonixin, 2,6-dinitro-p-cresol (DNPC), triclopyr, fluroxypyr, bisphenol S, picloram, and mesotrione. We further co-crystallized TTR with PBS, clonixin, DNPC, and triclopyr, and their complex structures showed that the compounds bind in the TBSs as proposed by the VS protocol. In summary, 13 indoor dust contaminants and industrial chemicals were identified as THDCs using a combination of in silico and in vitro approaches. To the best of our knowledge, none of these compounds has previously been reported to bind to TTR or THR. The identifications of these THDCs improve our understanding on the structure-activity relationships of THDCs. The crystal structures of TTR-THDC complexes and the information on THDC-Target intermolecular interactions provide a better understanding on the mechanism-of-actions behind thyroid disruption. The dataset compiled and in silico methods developed serve as a basis for identification of more diverse THDCs in the future and a tool for guiding de novo design of safer replacements.

Alterações genéticas nos genes RET, RAS e BRAF resultam na ativação constitutiva da sinalização MAPK e estão presentes em aproximadamente 70% dos carcinomas papilífero de tiroide, a forma mais prevalente de câncer de tiroide. Múltiplas vias de sinalização podem atuar em conjunto com a via MAPK na oncogênese tiroidiana. Nesse estudo, testamos a hipótese que a via MAPK regula a sinalização Notch e que o crosstalk entre as vias de sinalizações são importantes na regulação da diferenciação e proliferação celular no câncer de tiroide. A ativação condicional dos oncogenes RET/PTC3 e BRAFT1799A em linhagem de célula folicular normal de tiroide aumentou a atividade da via de sinalização Notch. Por outro lado, o bloqueio farmacológico da sinalização MAPK reduziu a sinalização Notch na linhagem celular TPC-1 derivada de carcinoma papilífero de tiroide. Glândulas tiroide de animais transgênicos expressando BRAFT1799A e amostras de carcinoma papilífero de tiroide apresentaram elevados níveis de NOTCH1. A superexpressão de NOTCH1 em célula folicular normal de tiroide aumentou a expressão proteica de NIS. A inibição farmacológica e por RNA de interferência da sinalização Notch apresentou um efeito anti-proliferativo em linhagem de CPT. Além disso, a combinação do inibidor farmacológico de Notch e MAPK diminuiu a proliferação de células de carcinoma papilífero de tiroide. Esses dados sugerem um importante papel da sinalização Notch na oncogênese do carcinoma papilífero de tiroide induzida pela sinalização MAPK e que a via Notch pode ser uma potencial terapia adjuvante no câncer de tiroide. / Genetic alterations in RET, RAS and BRAF result in constitutive activation of the MAPK signaling and are present in approximately 70% of papillary thyroid carcinomas, the most prevalent form of thyroid cancer. Multiple signaling pathways can act with MAPK pathway in thyroid oncogenesis. In this study, we tested the hypothesis that MAPK pathway control Notch signaling and that the crosstalk between these pathways plays an important role in thyroid cancer cell differentiation and proliferation. The conditional activation of RET/PTC3 and BRAFT1799A enhanced Notch signaling pathway in normal follicular thyroid cell. By contrast, pharmacological inhibition of MAPK reduced Notch signaling in TPC-1 cell line derived from papillary thyroid carcinoma. Transgenic mice expressing BRAFT1799A restrict in thyroid gland and human papillary thyroid carcinoma samples showed higher Notch1 expression. NOTCH1 overexpression in normal thyroid follicular cell increased NIS protein expression. Pharmacological inhibition and RNA interference of Notch signaling showed an anti-proliferative effect in papillary thyroid carcinoma cells. Furthermore, the combination of MAPK and Notch signaling inhibitors reduced papillary thyroid carcinoma proliferation. These data suggest an important role of Notch signaling in papillary thyroid carcinoma induced by MAPK-related oncogenes and that Notch signaling pathway could be a potential adjuvant therapy in thyroid cancer.

Fan, Dahua. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 117-155). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts also in Chinese.